Australian Government

Department of Veterans' Affairs

ELECTRONIC RECORDS

NB: These documents have been obtained from an electronic record. An original hard-copy version of this record does not exist.

DATA REQUEST - 9650 - EXT - FOI - LEX 78597 - Ketamine Infusion

Released 17 October 2025

Explanatory Notes

This data has been requested to provide the total number of treatment requests and the aggregate cost totals for intravenous ketamine infusion treatment for mental health conditions by DVA, for calendar periods from 1 January 2022 to the date of the search.

This data has been derived from two sources:

- **From 1 January 2022 – 1 October 2023:** Data extracted from Microsoft Excel spreadsheets held by the Medical and Allied Health Program team, recording all intravenous ketamine approvals by DVA.

- **From 1 October 2023 – to date:** Data extracted from DMIS Integrated Client (IC) Package and Teradata (Enterprise Data Warehouse (EDW)), based on Service Item Code MT62 [Intravenous Ketamine Therapy (IV Ketamine)].

Data extracted from DMIS IC EDW is current as of 3 October 2025.

Please be advised that this data should only be viewed in context with the notes, caveats and exclusions listed below:

- The figures for calendar year 2023 are significantly lower than 2022, 2024 and 2025 due to the introduction of Service Item Code MT62 on 1 October 2023. There may have been some overlap between the introduction of the new service code and the cessation of the use of other treatment codes for intravenous ketamine infusion treatment, meaning that there are approvals not captured in the below data. Due to differences in data reporting prior to and after 1 October 2023, it is not possible to obtain accurate data about these approvals.

- Please note that the DMIS approvals data for 1 October 2023 – to date, contains repeat approvals. Thus, the total number of approvals may be highly underestimated. Approvals data is sourced from DMIS report ICPA04.

- The aggregate cost for 1 October 2023 to date, is the total cost of MT62 that has been supplied. It is the amount paid to the payee provider by Services Australia on behalf of DVA.

Table 1.1 - Ketamine infusion - MT62 (Intravenous Ketamine Therapy) approvals from 1 January 2022 to 3 October 2025

Calendar Year	Number of approvals	Total cost of item supplied
2022	166	$1,020,877.05
2023	126	$795,721.75
2024	513	$1,685,425.58
2025 (to date)	286	$1,813,615.64